WS #14981

The geopolitical landscape has sharply deteriorated as the US formally rejected Iran's proposal to reopen the Strait of Hormuz, pushing the conflict narrative from containment to active escalation. This rejection has triggered a massive repricing in energy markets, with Brent crude surging approximately 4% to $108.50 and tanker rates hitting $1 million per day. The resulting stagflationary shock—simultaneously driving oil higher and 30-year Treasury yields to 5.535%—is forcing a defensive rotation out of growth equities, with S&P 500 and Nasdaq futures slipping 0.5% to 1% in premarket trading. The narrative arc has decisively shifted from a 'ceasefire hope' to a 'war premium' reality, pressuring consumer discretionary, airlines, and high-multiple tech while elevating energy and defense sectors. In corporate developments, Nvidia's authorization of a $150 billion increase to its share repurchase program (bringing the total authorization to $235 billion) stands as the singular dominant positive signal in an otherwise risk-off environment. This massive capital return program signals management's conviction in the sustainability of AI demand and provides a floor for the stock despite the broader macro headwinds. Conversely, Snowflake's announcement of a $3.5 billion convertible note issuance introduces near-term dilution concerns and adds supply to the market, creating a mixed-to-negative signal for the high-growth software sector amidst rising rate fears. The defense sector is seeing a secondary surge driven by direct kinetic escalation, specifically a Russian strike on Ukraine's National Academy of Sciences and Ukrainian retaliatory strikes on Russian oil facilities. This confirms the 'escalation' theme state and validates the rotation into defense names. Meanwhile, the pharmaceutical sector remains active with Merck securing exclusive global rights to the KRAS inhibitor SPR2015, a significant deal that offsets broader biotech volatility, while Pfizer continues its strategic pivot toward oncology and obesity treatments to offset declining COVID-era revenues.